366 related articles for article (PubMed ID: 25933216)
1. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma.
Malo CS; Renner DN; Huseby Kelcher AM; Jin F; Hansen MJ; Pavelko KD; Johnson AJ
PLoS One; 2016; 11(8):e0162064. PubMed ID: 27560502
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
4. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
[TBL] [Abstract][Full Text] [Related]
5. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
6. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma.
Dey M; Chang AL; Miska J; Wainwright DA; Ahmed AU; Balyasnikova IV; Pytel P; Han Y; Tobias A; Zhang L; Qiao J; Lesniak MS
J Immunol; 2015 Jul; 195(1):367-76. PubMed ID: 26026061
[TBL] [Abstract][Full Text] [Related]
7. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
8. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
10. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
[TBL] [Abstract][Full Text] [Related]
11. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
[TBL] [Abstract][Full Text] [Related]
12. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
13. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.
Maes W; Rosas GG; Verbinnen B; Boon L; De Vleeschouwer S; Ceuppens JL; Van Gool SW
Neuro Oncol; 2009 Oct; 11(5):529-42. PubMed ID: 19336528
[TBL] [Abstract][Full Text] [Related]
14. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
15. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
[TBL] [Abstract][Full Text] [Related]
16. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.
Iizuka Y; Kojima H; Kobata T; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2006 Feb; 118(4):942-9. PubMed ID: 16152596
[TBL] [Abstract][Full Text] [Related]
17. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
18. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.
Meng JZ; Dong YJ; Huang H; Li S; Zhong Y; Liu SL; Wang YD
Clin Vaccine Immunol; 2010 Jun; 17(6):889-94. PubMed ID: 20375244
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]